10-K/A: Apellis Pharmaceuticals Files 10-K/A Amendment
Form 10-K/A Amendment
Apellis Pharmaceuticals, Inc. has filed an Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, to include Part III information previously omitted.
Summary
- This filing is an Amendment No. 1 to Apellis Pharmaceuticals, Inc.'s Annual Report on Form 10-K for the fiscal year ended December 31, 2025.
- The amendment was filed to include information required by Part III of Form 10-K, specifically Items 10 through 14.
- This information was initially omitted in reliance on a general instruction that allows incorporation by reference from a definitive proxy statement, but the company will not be filing its proxy statement within the required timeframe.
- The amendment also removes the previous reference to incorporation by reference on the cover page of the original filing.
- New certifications from the principal executive and financial officers are included as exhibits.
- This amendment does not alter the financial statements or other information presented in the original filing and does not reflect events occurring after the original filing date.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this filing as neutral, as it is a procedural amendment to fulfill regulatory requirements and does not introduce new financial or strategic information.
Future Outlook
This amendment does not contain new forward-looking statements or guidance; it solely provides previously omitted Part III information from the original Form 10-K filing for the fiscal year ended December 31, 2025.
Industry Context
StockSavvy.ai notes that this filing is a procedural amendment to a standard annual report, ensuring compliance with SEC disclosure requirements. It does not contain new operational or financial performance data but rather completes the disclosure for Part III of the Form 10-K.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Inclusion of Part III Information | The amendment includes Items 10-14 of Part III of Form 10-K, covering Directors, Executive Officers and Corporate Governance; Executive Compensation; Security Ownership of Certain Beneficial Owners and Management; Certain Relationships and Related Transactions, and Director Independence; and Principal Accountant Fees and Services. | 2026-04-28 | Ensures full compliance with SEC reporting requirements for the annual report. |
Stakeholder Impact
- Shareholders: Receive complete disclosure for Part III of the annual report, enhancing transparency regarding governance, compensation, and ownership.
- Management: Have provided updated certifications as required by the amendment.
- Regulatory Bodies: Receive the necessary filings to ensure compliance with securities laws.
Next Steps
- The company will need to file its definitive proxy statement at a later date, or ensure all required Part III information is included in future filings.
Key Dates
| Date | Description |
|---|---|
| 2025-12-31 | Fiscal year ended |
| 2026-02-24 | Original Form 10-K filing date |
| 2026-04-21 | Date as of which number of outstanding shares was reported |
| 2026-04-28 | Filing date of Amendment No. 1 |
Keywords
10-K/A, Amendment, Apellis Pharmaceuticals, SEC Filing, Annual Report, Part III, Corporate Governance, Executive Compensation, Stock Ownership, Related Transactions, Accountant Fees
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.